Movers and Shakers within Pharma
Pharma IQ takes a look at some of the industry’s most prestigious movers and shakers causing ripples in the market over the last few months.
CEO Sir Andrew Witty to retire after 32 years at GSK
Last month, GSK plc revealed to shareholders that it’s CEO of 10 years Sir Andrew Witty has indicated his intention to retire from the company. The move is scheduled to occur at the end of Q1 next year and until then the firm is searching for his successor. Sir Witty spent a total of 32 years at the pharmaceutical firm.
Martin Shkreli steps down
Last month it was announced that Martin Shkreli, who faced fierce media criticism over the pricing of HIV drug Daraprim, stepped down from his position as CEO at Turing Pharmaceuticals, with Ron Tilles stepping in as interim CEO.
Graham Walker heads from AstraZeneca to Idea Pharma
In response to the new recruit, who has over 20 years of industry experience, in an online statement Mike Rea IDEA Pharma’s CEO commented: “We’re constantly on the hunt for the very best intellectual, creative and innovative minds, as we’re recognised leaders now in this industry. Graham’s appointment further strengthens our position.”
Mike Pearson to step down from CEO position at Valeant
Valeant Pharmaceuticals announced that Michael Pearson’s term as CEO for the company would be coming to an end once his successor is named.
"It's been a privilege to lead Valeant for the past eight years," said J. Michael Pearson, chief executive officer. "While I regret the controversies that have adversely impacted our business over the past several months, I know that Valeant is a strong and resilient company, and I am committed to doing everything I can to ensure a smooth transition to new leadership."
Lumos Pharma welcomes David M Weiner
David Weiner joins the company to fill Lumos Pharma’s Inc Chief Medical Officer position. He previously performed the same role at Tyr Pharma and Proteostasis Therapeutics. In reaction to his new role with the biotech firm, Dr Weiner said: "I am excited to be joining Lumos Pharma at this important time in the company's evolution as we prepare for our first formal meeting with the FDA, and continue to advance the development of our pipeline. "
Cancer Genomics firm appoints ex-Archimedes Pharma Ltd CEO
Inviata Limited recently appointed Jeffrey Buchalter as its Non-executive Director and Board Chairman.
|Have Your Say|
Rate this feature and give us your feedback in the comments section below